Navelbine (Vinorelbine Tartrate)

Vinorelbine Tartrate, the active ingredient in Navelbine, is a Vinca alkaloid presented as a capsule for oral use. It treats certain types of lung and breast cancer in adult patients.

GNH USA supplies Navelbine as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Navelbine (vinorelbine tartrate) is used in oncology to target rapidly dividing tumor cells.

- Non‑small cell lung cancer: improves disease control and prolongs survival in eligible patients. - Metastatic breast cancer: reduces tumor burden and extends progression‑free survival. - Combination regimens for NSCLC: used together with platinum‑based chemotherapy to enhance response rates.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Anemia: lowered red blood cell levels causing fatigue. - Nausea: sensation of needing to vomit, often mild to moderate. - Constipation: decreased bowel movements and abdominal discomfort.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Pulmonary toxicity: inflammation or fibrosis of lung tissue. - Peripheral neuropathy: tingling, numbness, or pain in extremities. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for toxicity.

- Monitor blood counts: perform regular CBCs to detect neutropenia or anemia. - Assess liver function: check hepatic enzymes as vinorelbine is metabolised hepatically. - Evaluate for neuropathy: watch for sensory changes and adjust dose if needed. - Avoid use in pregnancy: category D; discontinue if pregnancy is confirmed. - Store at ambient temperature: keep capsules in the original container, protect from moisture and direct sunlight.

Vinorelbine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase vinorelbine exposure. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic levels. - Concurrent myelosuppressive chemotherapy: heightens risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding risk; monitor INR. - Antiemetic agents (e.g., ondansetron): may require dose adjustment for additive effects.